Oxford Asset Management’s Neurogene NGNE Stock Holding History

Oxford Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,589	Closed	-$148K	–	1978
2019 Q3	$148K	Sell	2,589 -6,020	-70%	-$367K	﹤0.01%	1604
2019 Q2	$406K	Sell	8,609 -2,001	-19%	-$103K	0.01%	1353
2019 Q1	$572K	Sell	10,610 -2,767	-21%	-$140K	0.01%	1154
2018 Q4	$578K	Buy	13,377 +637	+5%	+$31K	0.02%	1132
2018 Q3	$747K	Buy	12,740 +6,544	+106%	+$386K	0.02%	1146
2018 Q2	$299K	Buy	6,196 +3,888	+168%	+$1.01M	0.01%	1496
2018 Q1	$650K	Buy	2,308 +547	+31%	+$151K	0.01%	1136
2017 Q4	$419K	Buy	+1,761	New	+$413K	0.01%	1237

Other funds holding NGNE

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oxford Asset Management's NGNE Position: Q4 2019 in Review

Oxford Asset Management sold out of Neurogene (NGNE) in Q4 2019, closing a stake of 2,589 shares — an estimated $148K sold.

Oxford Asset Management first reported a position in NGNE in Q4 2017 and held it in 8 quarters. The position peaked at $747K in Q3 2018. 55 funds tracked by Wall St. Rank hold NGNE as of Q4 2019.

Oxford Asset Management reported no remaining Neurogene position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 2,589 Neurogene shares in Q4 2019, an estimated $148K.
Oxford Asset Management first reported a position in Neurogene in Q4 2017 and held it in 8 quarters.
Oxford Asset Management's Neurogene position peaked at $747K in Q3 2018.
55 funds tracked by Wall St. Rank held Neurogene as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.